Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Multiple Sclerosis
In brief
The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week Core Study (ONO-4641POU006 \[NCT01081782\]).
Key facts
- Study ID
- NCT01226745
- Run by
- EMD Serono
- People needed
- 340
- Starts
- 2010-10-01
- Expected to finish
- 2015-01-01
- Last updated by the study team
- 2016-07-12
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Completed 26 weeks of double-blind phase of Study ONO-4641POU006
You may not qualify if…
- Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer
Where it is running
- Aurora Clinical Site 132 — Aurora, Colorado, United States
- Fort Collins Clinical Site 123 — Fort Collins, Colorado, United States
- Fairfield Clinical Site 110 — Fairfield, Connecticut, United States
- Ormond Beach Clinical Site 129 — Ormond Beach, Florida, United States
- Sarasota Clinical Site 116 — Sarasota, Florida, United States
- Northbrook Clinical Site 135 — Northbrook, Illinois, United States
- Fort Wayne Clinical Site 111 — Fort Wayne, Indiana, United States
- Indianapolis Clinical Site 121 — Indianapolis, Indiana, United States
- Detroit Clinical Site 104 — Detroit, Michigan, United States
- Farmington Hills Clinical Site 126 — Farmington Hills, Michigan, United States
- Lebanon Clinical Site 115 — Lebanon, New Hampshire, United States
- Albuquerque Clinical Site 106 — Albuquerque, New Mexico, United States
- Rochester Clinical Site 108 — Rochester, New York, United States
- Charlotte Clinical Site 125 — Charlotte, North Carolina, United States
- Raleigh Clinical Site 103 — Raleigh, North Carolina, United States
- Akron Clinical Site 112 — Akron, Ohio, United States
- Philadelphia Clinical Site 120 — Philadelphia, Pennsylvania, United States
- Knoxville Clinical Site 134 — Knoxville, Tennessee, United States
- Round Rock Clinical Site 107 — Round Rock, Texas, United States
- Brugge Clinical Site 203 — Bruges, Belgium
- La Louviere Clinical Site 201 — La Louvière, Belgium
- Vancouver Clinical Site 131 — Vancouver, British Columbia, Canada
- Gatineau Clinical Site 114 — Gatineau, Quebec, Canada
- Greenfield park Clinical Site 109 — Greenfield Park, Quebec, Canada
- Tucson Clinical Site 133 — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.